Use of Leflunomide as a treatment for paediatric chronic uveitis
Reviewed by Fiona Rowe

Leflunomide is a disease modifying anti-rheumatic drug approved for treatment of rheumatoid arthritis and psoriatic arthritis in adult patients. This study reports five illustrative case reports of children using Leflunomide as an adjunct treatment with anti-tumour necrosis factor (TNF) agents for chronic uveitis who did not tolerate methotrexate. Children were aged nine or 11 years; three female and two male. Duration of steroid-free remission was 6, 8, 6, 24 and 24 months. The authors discuss the need for more data to support this monotherapy in paediatric uveitis. Their experience is that Leflunomide is well tolerated and effective in conjunction with anti-TNF agents where methotrexate is not tolerated.

The effect of Leflunomide as adjunctive therapy with a TNF inhibitor in pediatric patients with uveitis.
Garg N, Cohen E, Tsui E, LaMattina KC.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2023;60:417–20.